Good post JP. These are all awesome milestones. One more point is the milestones he can't mention in that list. All the NDA's that limit what he can say about certain things. For example, anything related to a spin off or Novartis. He did state in a regent blog for the potential of MANF biz dev opportunities. These are the things that he can't include in his list that are the really big value drivers.